The role of melatonin in multiple sclerosis, huntington's disease and cerebral ischemia

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 6, 2014, Pages 1096-1119

  Escribano, Begoña M ^a   Colín González, Ana L ^b   Santamaría, Abel ^b   Túnez, Isaac ^a  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Huntington s disease; Melatonin; Multiple sclerosis; Neurodegeneration; Neuroprotection; Oxidative stress; Stroke

Indexed keywords

MELATONIN; MELATONIN RECEPTOR; NEUROHORMONE; TRANSCRIPTION FACTOR NRF2;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CIRCADIAN RHYTHM; CYTOSKELETON; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PINEAL BODY; RISK FACTOR; SIGNAL TRANSDUCTION; SLEEP DISORDER; METABOLISM;

BRAIN ISCHEMIA; DISEASE PROGRESSION; HUMANS; HUNTINGTON DISEASE; MELATONIN; MULTIPLE SCLEROSIS;

EID: 84926366235     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666140806160400     Document Type: Article

References (318)

1. Reiter RJ. Melatonin: the chemical expression of darkness. Mol Cell Endocrinol 1991; 79: C153-8.
2. Stefuli J, Hortner M, Ghosh M, et al. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J Pineal Res 2001; 30: 243-7.
3. Slominski J, Pisarchik A, Semak I, et al. Serotoninergic and melatoninergic systems are fully expressed in human skin. FASEB J 2002; 16: 896-8.
4. Tan DX, Reiter RJ, Manchester LC, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2: 181-97.
5. Tan DX, Manchester LC, Hardeland R, et al. Melatonin: a hormone, a tissue factor, and autocoid, a paracoid and an antioxidant vitamin. J Pineal Res 2003; 34: 75-8.
6. Esposito E, Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 2010; 8: 228-42.
7. Wang X, Siriani A, Pei Z, et al. The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J Neurosci 2011; 31: 14496-507.
8. Maldonado MD, Siu AW, Sánchez-Hidalgo M. Melatonin and lipid uptake by murine fibroblasts: clinical implications. Neuroendocrinol Lett 2006; 27: 601-8.
9. García-Navarro A, Gónzalez-Puga C, Escames G, et al. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 2007; 43: 195-205.
10. Sánchez-Hidalgo M, Lu Z, Tan DX. Melatonin inhibits fatty acid induced triglyceride accumulation in TOS 17/2.8 cells: implications for osteoblast differentiation and osteoporosis. Am J Physiol Regul Integr Comp Physiol 2007; 292: 2208-15.
11. Paparrigopoulus T, Psarros C, Bergiannaki J, et al. Melatonin response to clonidine administration in depression: indication of presynaptic alpha2-adrenoceptor dysfunction. J Affect Disord 2001; 65: 307-13.
12. Waldhauser F, Waldhauser M, Lieberman HR, et al. Bioavailability of oral melatonin in humans. Neuroendocrinol 1984; 39: 307-13.
13. Maldonado MD, Mora-Santos M, Naji L, et al. Evidence of melatonin synthesis and release by mast cells. Possible modulatory role on inflammation. Pharmacol Res 2010; 62: 282-7.
14. El-Shenawy SH, Omar ME, Abdel-Salam OME, et al. Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat. Pharmacol Res 2002; 46: 235-43.
15. Padillo FJ, Ruiz-Rabelo JF, Cruz A, et al. Melatonin and celecoxib improve the outcomes in hámster with experimental pancreatic cancer. J Pineal Res 2010; 49: 264-70.
16. Sariahmetoglu M, Wheatley RA, Çakycy Y, Kanzyka Y, Townshend A. Evaluation of the antioxidant effect of melatonin by flow injection analysis-luminol chemiluminescence. Pharmacol Res 2003; 48: 361-7.
17. Reiter RJ, Tan DX, Gultekin F. Melatonin reduces molecular damage and physiological dysfunction in experimental models of neurodegeneration. In: Melatonin present and future; Túnez I; Montilla P, Eds; Nova Science Publishers Inc: New York 2007; pp. 261-97.
18. Srinivasan V, Pandi-Perumal SR, Cardinali DP, Peggeler B, Hardeland R. Melatonin in Alzheimer’disease and other neurodegenerative disorders. Behav Brain Funct 2006; 2: 15.
19. Túnez I, Montilla P. Neuroprotective role of melatonin against Alzheimer’s disease, Huntington’s disease and other cerebral disorders. In: Melatonin present and future; Túnez I; Montilla P, Eds; Nova Science Publishers Inc: New York 2007; pp. 315-47.
20. Weishaupt JH, Bartels C, Pölking E, et al. Ehrenreich H. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006; 41: 313-23.
21. Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, et al. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’disease. A randomized, double blind, placebo-controlled study. J Neurol 2007; 254: 459-64.
22. Kilic E, Kilic U, Yulug B, Hermann DM, Reiter RJ. Melatonin reduces disseminate neuronal death after mild focal ischemia in mice via inhibition of caspase-3 and is suitable as an add-on treatment to tissue-plasminogen activator. J Pineal Res 2004; 36: 171-6.
23. Domínguez-Rodríguez A, Abreu-González P, García-González MJ, et al. A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an adjunct in patients with acute myocardial infarction undergoing primary angioplasty: the melatonin adjunct in the acute myocardial infarction treated with angioplasty (MARIA) trial: study design and rationale. Contemp Clin Trials 2007; 28: 532-9.
24. Gupta M, Aneja S, Kohli K. Add-on melatonin improves quality of life in epileptic children on valproate monotherapy: a randomized double-blind, placebo-controlled trial. Epilepsy Behav 2004; 5: 316-21.
25. Savina TA, Balashova OA, Shchipakina TG. Effect of chronic consumption of sodium valproate and melatonin on seizure activity in Krushinskii-Molodkina rats. Bull Exp Biol Med 2006; 142: 601-4.
26. Ozdemir D, Usyal N, Gonenc S, et al. Effect of melatonin on brain oxidative damage induced by traumatic brain injury in immature rats. Physiol Res 2005; 54: 631-7.
27. Cardinali DP, Pagano ES, Scacchi-Bernasconi PA, Reynoso R, Scacchi P. Melatonin and mitocondrial dysfunction in the central nervous system (Review). Horm Behav 2013; 63: 322-30.
28. Johri A, Beal MF. Antioxidants in Huntington’disease. Biochim Biophys Acta 2012; 1822: 664-74.
29. Srinivasan V, Pandi-Perumal SR, Maestroni GJ, et al. Role of melatonin in neurodegenerarive diseases. Neurotox Res 2005; 7: 293-318.
30. Frauke Zipp F, Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 2006; 29: 518-27.
31. Caine ED, Bamford KA, Schiffer RB, Shoulson I, Levy S. A controlled neuropsychological comparison of Huntington's Disease and Multiple Sclerosis. Arch Neurol 1986; 43: 249-54.
32. De Lago E, Fernández-Ruiz J, Ortega-Gutiérrez S, et al. UCM707: an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington’s disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. Eur Neuropsychopharmacol 2006; 16: 7-18.
33. Roos RAC. Huntington’disease: a clinical review. OJRD 2010; 5: 40. Available online: http://www.ojrd.com/content/5/1/40 (accessed on 14 October 2013).
34. National Pediatric MS Center (n.d.) Guide for nurses. Available on line: http://www.pediatricmscenter.org/professionals/nurses (accessed on 4 October 2013).
35. Ramaswamy S, Shannon KM, Kordower JH. Huntington’s disease: pathological mechanisms and therapeutic strategies. Cell Transplant 2007; 16: 1-100.
36. Kieseier BC, Wiendl H, Hartunga HP, Stüve O. Perspective: The future of multiple sclerosis therapy. Pharmacol Res 2009; 60: 207-11.
37. Sarlak G, Jenwitheesuk A, Chetsawang A, Govitrapong P. Effects of Melatonin on Nervous System Aging: Neurogenesis and Neurodegeneration. J Pharmacol Sci 2013; 123: 9-24.
38. Coto-Montes A, Antonio Boga J, Rosales-Corral S, et al. Role of melatonin in the regulation of autophagy and mitophagy: A review. Mol Cell Endocrinol 2012; 361: 12-23.
39. Luchetti F, Canonico B, Betti M, et al. Melatonin signaling and cell protection function. FASEB J 2010; 24: 3603-24.
40. Korkmaz A, Sergio Rosales-Corral, Russel J. Reiter. Gene regulation by melatonin linked to epigenetic phenomena. Gene 2012; 503: 1-11.
41. Lerner AB, Case JD, Takahashi Y, Lee TH, Mori N. Isolation of melatonin, pineal factor that lightens melanocytes. J Am Chem Soc 1958; 80: 2587.
42. Lerner AB, Case JD, Heinzelman RU. Structure of melatonin. J Am Chem Soc 1959; 81: 6084-5.
43. Vijayalaxmi TRC, Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002; 20: 2575-601.
44. Pandi-Perumal SR, Srinivassan V, Maestroni GJM, et al. Melatonin. Nature’s most versatile biological signal? FEBS J 2006; 273: 2813-36.
45. Karasek M. Melatonin in human physiology and pathology. In Frontiers in Chronobiology Research, F Columbus (ed). Hauppage, NY, Nova Science 2006; pp. 1-43.
46. Harderland R, Poeggeler B. Non-vertebrate melatonin. J Pineal Res 2003; 34: 233-41.
47. Arendt J. Melatonin and the mammalian pineal gland. London, Chapman & Hall 1995.
48. Karasek M. Melatonin in humans-where we are 40 years after its discovery. Neuroendocrinol Lett 1999; 20: 179-88.
49. Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab 2003; 17: 273-85.
50. Lane EA, Moss HB. Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab 1985; 61: 1214-6.
51. Brown EN, Choe Y, Shanahan TL, Czeisler CA. A mathematical model of diurnal variations in human plasma melatonin levels. Am J Physiol 1997; 272: E506-16.
52. Hardeland R. Melatonin metabolism in the central nervous system. Curr Neuropharmacol 2010; 8: 168-81.
53. Lahiri DK, Ge YW, Sharman EH, Bondy SC. Age-related changes in serum melatonin in mice: higher levels of combined melatonin and 6-hydroxymelatonin sulfate in the cerebral cortex than serum, heart, liver and kidney tissues. J Pineal Res 2004; 36: 217-23.
54. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007; 42: 28-34.
55. Onuki J, Almeida EA, Medeiros MH, Di Mascio P. Inhibition of 5-aminolevulinic acid-induced DNA damage by melatonin, N1-acetyl-N2-formyl-5-methoxykynuramine, quercetin or resveratrol. J Pineal Res 2005; 38: 107-15.
56. Silva SO, Ximenes VF, Livramento JA, Catalani LH, Campa A. High concentrations of the melatonin metabolite, N1-acetyl-N2-formyl-5-methoxykynuramine, in cerebrospinal fluid of patients with meningitis: a possible immunomodulatory mechanism. J Pineal Res 2005; 39: 302-6.
57. Tan DX, Manchester LC, Sainz RM, et al. Interactions between melatonin and nicotinamide nucleotide: NADH preservation in cells and in cell-free systems by melatonin. J Pineal Res 2005; 39: 185-94.
58. Ressmeyer AR, Mayo JC, Zelosko V, et al. Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep 2003; 8: 205-13.
59. Carampin P, Rosan S, Dalzoppo D, Zagotto G, Zatta P. Some biochemical properties of melatonin and the characterization of a relevant metabolite arising from its interaction with H2O2. J Pineal Res 2003; 34: 134-42.
60. Tan DX, Manchester LC, Burkhardt S, et al. N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J 2001; 15: 2294-6.
61. Mayo JC, Sainz RM, Tan DX, et al. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK): in macrophages. J Neuroimmunol 2005; 165: 139-49.
62. Silva SO, Rodrigues MR, Ximenes VF, et al. Neutrophils as a specific target for melatonin and kynuramines: effects on cytokine release. Neuroimmunology 2004; 156: 146-52.
63. Hardeland R, Pandi-Perumal SR. Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr Metab (Lond): 2005; 10: 22.
64. Sugden D. Melatonin biosynthesis in the mammalian pineal gland. Experientia 1989; 45: 922-31.
65. Dubocovich ML, Cardinali DP, Delagrange P, et al. Melatonin receptors. In The IUPHAR Compendium of Receptor Characterization and Classification, 2nd edition, IUPHAR Media, London, UK 2000; pp. 270-7.
66. Slaugenhaupt SA, Roca AL, Liebert CB, et al. Mapping of the gene for the Mel1a melatonin receptor to human chromosome 4 (MTNR1A) and mouse chromosome 8 (Mtnr1a). Genomics 1995; 27: 355-7.
67. Reppert SM, Godson C, Mahle CD, et al. Molecular characterization of second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci USA 1995; 92: 8734-8.
68. Godson C, Reppert SM. The Mel1a melatonin receptor is coupled to parallel signal transduction pathways., Endocrinology 1997; 138: 397-404.
69. Petit L, Lacroix I, Coppet P, Strosberg AD, Jockers R. Differential signaling of human Mel1a and Mel1b melatonin receptors trough the cyclic guanosine 3’-5’-momphosphate pathway. Biochem Pharmacol 1999; 58: 633-9.
70. Mazzuchelli C, Pannacci M, Nonno R, et al. The melatonin receptor in the human brain: cloning experiments and distribution studies. Mol Brain Res 1996; 39: 117-26.
71. Al-Ghoul WM, Herman MD, Dubocovich ML. Melatonin receptor subtype expression in human cerebellum. Neuroreport 1998; 9: 4063-8.
72. Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother 2006; 60: 97-108.
73. Musshoff U, Riewenherm D, Berger E, Fauteck JD, Speckmann EJ. Melatonin receptors in rat hippocampus: molecular and functional investigations. Hippocampus 2002; 12: 165-73.
74. Comai S, Gobbi G. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. J Psychiatry Neurosci 2013; 38: 130009
75. Becker-Andre M, Andre E, De Lamarter JF. Identification of nuclear receptor mRNAs by RT-PCR amplification of conserved zinc-finger motif sequences. Bioch Biophys Res Commun 1993; 194: 1371-9.
76. Becker-Andre M, Wiesenberg I, Schaeren-Wiemers N, et al. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem 1994; 269: 28531-4.
77. Giguere V, Tini M, Flock G, et al. Isoform-specific amino-terminal domains dictate DNA-binding properties of RORa, a novel family of orphan hormone nuclear receptors. Gen Dev 1994; 8: 538-53.
78. Giguere V. Orphan nuclear receptors: from gene to function. Endocrine Rev 1999; 20: 689-725.
79. Provinciali M, Di Stefano G, Bulina D, Tibaldi A, Fabris N. Effect of melatonin and pineal grafting on thymocytes apoptosis in aging mice. Mech Ageing Dev 1996; 90: 1-19.
80. Cagnoli CM, Atabay C, Kharfamova E, Manew H. Melatonin protects neurons from singlet oxygen-induced apoptosis. J Pineal Res 1995; 18: 222-6.
81. Deigner HP, Haberkorn U, Kinscherf R. Apoptosis modulators in the therapy of neurodegenerative diseases. Exp Opin Investig Drugs 2000; 9: 747-64.
82. Sainz RM, Mayo JC, Rodriguez C, et al. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 2003; 60: 1407-26.
83. Melen-Mucha G, Winczyk K, Pawlikowski M. Somatostatin analogue octreotide and melatonin inhibit bromodeoxyuridine incorporation into cell nuclei and enhance apoptosis in the transplantable muurine Colon 38 cancer. Anticancer Res 1998; 18: 3615-20.
84. Winczyk K, Pawlikowski M, Karasek M. Melatonin and RZR/ROR receptor ligand CGP 52 608 induce apoptosis in the murine colonic cancer. J Pineal Res 2001; 31: 179-82.
85. Winczyk K, Pawlikowski M, Guerrero JM, Karasek M. Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine Colon 38 cancer. Tumor Biol 2002; 23: 298-302.
86. Karasek M, Gruszka A, Lawnicka H, Kunert-Radek J, Pawlikowski M. Melatonin inhibits growth of diethylstilbestrol-induced prolactin-secreting pituitary tumor in vitro: possible involvement of nuclear RZR/ROR receptors. J Pineal Res 2003; 34: 1-3.
87. Dai J, Inscho EW, Yuan L, Hill SM. Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells. J Pineal Res 2002; 32: 112-9.
88. Sánchez-Barcelo EJ, Cos S, Mediavilla D, Martinez-Campa G, Alonso-González C. Melatonin-estrogen interactions in breast cancer. J Pineal Res 2005; 38: 217-22.
89. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200.
90. Pozo D, Garcia-Maurino S, Guerrero JM, Calvo JR. mRNA expression of nuclear RZR/ROR alpha, membrane receptor MT, and hydroxyindole-O-methyltransferase in different populations of human immune cells. J Pineal Res 2004; 37: 48-54.
91. Steinhilber D, Brungs M, Werz O, et al. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J Biol Chem 1995; 270: 7040-73.
92. Reiter RJ. Interactions of the pineal hormone melatonin with oxygen-centered free radicals: a brief review. Braz J Med Biol Res 1993; 26: 1141-55.
93. Barlow-Walden LR, Reiter RJ, Abe M, et al. Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 1995; 26: 497-502.
94. Montilla P, Túnez I, Muñoz MC, Soria JV, López A. Antioxidative effect of melatonin in rat brain oxidative stress induced by Adriamycin. Rev Esp Fisiol 1997; 53: 301-5.
95. Matuszak Z, Reszka K, Chignell CF. Reaction of melatonin and related indoles with hydroxyl radicals: EPR and spin trapping investigations. Free Radic Biol Med 1997; 23: 367-72.
96. Jung KH, Hong SW, Zheng HM, Lee DH, Hong SS. Melatonin downregulates nuclear erythroid 2-related factor 2 and nuclear factor-kappaB during prevention of oxidative liver injury in a dimethylnitrosamine model. J Pineal Res 2009; 47: 173-83.
97. Reiter RJ, Tan DX, Terron MP, Flores LJ, Czarnocki Z. Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochim Pol 2007; 54: 1-9.
98. Steinhilber D, Brungs M, Werz O, et al. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes. J Biol Chem 1995; 270: 7037-40.
99. Pozo D, Reiter RJ, Calvo JR, Guerrero JM. Physiological concentrations of melatonin inhibit nitric oxide synthase in rat cerebellum. Life Sci 1994; 55: PL455-60.
100. Bettahi I, Pozo D, Osuna C, et al. Melatonin reduces nitric oxide synthase activity in rat hypothalamus. J Pineal Res 1996; 20: 205-10.
101. Poeggeler B, Reiter RJ, Tan DX, Chen LD, Manchester LC. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. J Pineal Res 1993; 14: 151-68.
102. Li XJ, Zhang LM, Gu J, Zhang AZ, Sun FY. Melatonin decreases production of hydroxyl radical during cerebral ischemiareperfusion. Zhongguo Yao Li Xue Bao 1997; 18: 394-6.
103. Reiter RJ, Tan DX, Burkhardt S. Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin. Mech Ageing Dev 2002; 30: 1007-19.
104. Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
105. Tan DX, Manchester LC, Reiter RJ, et al. Melatonin directly scavenges hydrogen peroxide: a potentially new metabolic pathway of melatonin biotransformation. Free Radic Biol Med 2000; 29: 1177-85.
106. Zhang H, Squadrito GL, Uppu R, Pryor WA. Reaction of peroxynitrite with melatonin: A mechanistic study. Chem Res Toxicol 1999; 12: 526-34.
107. Marshall KA, Reiter RJ, Poeggeler B, Aruoma OI, Halliwell B. Evaluation of the antioxidant activity of melatonin in vitro. Free Radic Biol Med 1996; 21: 307-15.
108. Sofic E, Rimpapa Z, Kundurovic Z, et al. Antioxidant capacity of the neurohormone melatonin. J Neural Transm. 2005; 112: 349-58.
109. Zhang L, Zhang HQ, Liang XY, et al. Melatonin ameliorates cognitive impairment induced by sleep deprivation in rats: Role of oxidative stress, BDNF and CaMKII. Behav Brain Res 2013; 256C: 72-81.
110. Jung KH, Hong SW, Zheng HM, et al. Melatonin ameliorates cerulein-induced pancreatitis by the modulation of nuclear erythroid 2-related factor 2 and nuclear factor-kappaB in rats. J Pineal Res 2010; 48: 239-50.
111. Tripathi DN, Jena GB. Effect of melatonin on the expression of Nrf2 and NF-kappaB during cyclophosphamide-induced urinary bladder injury in rat. J Pineal Res 2010; 48: 324-31.
112. Crespo I, Miguel BS, Laliena A, et al. Melatonin prevents the decreased activity of antioxidant enzymes and activates nuclear erythroid 2-related factor 2 signaling in an animal model of fulminant hepatic failure of viral origin. J Pineal Res 2010; 49: 193-200.
113. Laothong U, Pinlaor P, Hiraku Y, et al. Protective effect of melatonin against Opisthorchis viverrini-induced oxidative and nitrosative DNA damage and liver injury in hamsters. J Pineal Res 2010; 49: 271-82.
114. Negi G, Kumar A, Sharma SS. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-κB and Nrf2 cascades. J Pineal Res 2011; 50: 124-31.
115. Liu Y, Zhang L, Zhang H, et al. Exogenous melatonin modulates apoptosis in the mouse brain induced by high-LET carbon ion irradiation. J Pineal Res 2012; 52: 47-56.
116. Wang Z, Ma C, Meng CJ, et al. Melatonin activates the Nrf2-ARE pathway when it protects against early brain injury in a subarachnoid hemorrhage model. J Pineal Res 2012; 53: 129-37.
117. Dwivedi S, Nagarajan R, Hanif K, et al. Standardized Extract of Bacopa monniera Attenuates Okadaic Acid Induced Memory Dysfunction in Rats: Effect on Nrf2 Pathway. Evid Based Complement Alternat Med 2013; 2013: 294501.
118. Menendez-Pelaez A, Reiter RJ. Distribution of melatonin in mammalian tissues: the relative importance of nuclear versus cytosolic localization. J Pineal Res 1993; 15: 59-69.
119. Martín M, Macías M, Escames G, León J, Acuña-Castroviejo D. Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress. FASEB J 2000; 14: 1677-9.
120. Paradies G, Petrosillo G, Paradies V, Reiter RJ, Ruggiero FM. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res 2010; 48: 297-310.
121. Tapias V, Escames G, López LC, et al. Melatonin and its brain metabolite N(1)-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice. J Neurosci Res 2009; 87: 3002-10.
122. Escames G, López LC, Tapias V, et al. Melatonin counteracts inducible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice. J Pineal Res 2006, 40: 71-8.
123. Chang CF, Huang HJ, Lee HC, et al. Melatonin attenuates kainic acid-induced neurotoxicity in mouse hippocampus via inhibition of autophagy and α-synuclein aggregation. J Pineal Res 2012; 52: 312-21.
124. Feng YM, Jia YF, Su LY, et al. Decreased mitochondrial DNA copy number in the hippocampus and peripheral blood during opiate addiction is mediated by autophagy and can be salvaged by melatonin. Autophagy 2013; 9.
125. Acuña-Castroviejo D, Escames G, León J, Carazo A, Khaldy H. Mitochondrial regulation by melatonin and its metabolites. Adv Exp Med Biol 2003; 527: 549-57.
126. Petrosillo G, Fattoretti P, Matera M, et al. Melatonin prevents agerelated mitochondrial dysfunction in rat brain via cardiolipin protection. Rejuvenation Res 2008; 11: 935-43.
127. Fu JL, Zhang HM, Zhang H, et al. A melatonin-based fluorescence method for the measurement of mitochondrial complex III function in intact cells. J Pineal Res 2013; 55(4): 364-70.
128. Sainz RM, Mayo JC, Rodriguez C, et al. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 2003; 60: 1407-26.
129. Wang X. The anti-apoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther 2009; 15: 345-57.
130. He H, Dong W, Huang F. Anti-Amyloidogenic and Anti-Apoptotic Role of Melatonin in Alzheimer Disease. Curr Neuropharmacol 2010; 8: 211-7.
131. Lahiri DK, Chen D, Ge YW, Bondy SC, Sharman EH. Dietary supplementation with melatonin reduces levels of amyloid betapeptides in the murine cerebral cortex. J Pineal Res 2004; 36: 224-31.
132. Zhang YC, Wang ZF, Wang Q, Wang YP, Wang JZ. Melatonin attenuates beta-amyloid-induced inhibition of neurofilament expression. Acta Pharmacol Sin 2004; 25: 447-51.
133. Dong W, Huang F, Fan W, et al. Differential effects of melatonin on amyloid beta peptide 25-35-induced mitochondrial dysfunction in hippocampal neurons at different stages of culture. J Pineal Res 2010; 48: 117-25.
134. Rodriguez C, Martín V, Herrera F, et al.. Mechanisms Involved in the Pro-Apoptotic Effect of Melatonin in Cancer Cells. Int J Mol Sci 2013; 14: 6597-613.
135. Costantino G, Cuzzocrea S, Mazzon E, Caputi AP. Protective effects of melatonin in zymosan-activated plasma-induced paw inflammation. Eur J Pharmacol 1998; 363: 57-63.
136. Cuzzocrea S, Zingarelli B, Gilad E, et al. Protective effect of melatonin in carrageenan-induced models of local inflammation: relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity. J Pineal Res 1997; 23: 106-16.
137. Bilici D, Akpinar E, Kiziltunç A. Protective effect of melatonin in carrageenan-induced acute local inflammation. Pharmacol Res 2002; 46: 133-9.
138. Carrillo-Vico A, Lardone PJ, Fernandez-Santos JM, et al. Human lymphocyte-synthesized melatonin is involved in the regulation of the interleukin 2/ interleukin 2 receptor system. J Clin Endocrinol Metab 2005; 90: 992-1000.
139. Carrillo-Vico A, Lardone PJ, Naji L, et al. Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects. J Pineal Res 2005; 39(4): 400-8.
140. Pozo D, Reiter RJ, Calvo JR, Guerrero JM. Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with calmodulin. J Cell Biochem 1997; 65: 430-42.
141. Pajovic SB, Saicic ZS, Spasic MB, Petrovic MB. The effect of ovarian hormones on antioxidant enzyme activities in the brain of male rats. Physiol Rev 2003; 52: 189-94.
142. Crespo E, Macıas M, Pozo D, et al. Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J 1999; 13: 1537-46.
143. Escames G, Leon J, Macıas M, et al. Melatonin counteracts lipopolysaccharide-induced expression and activity of mitochondrial nitric oxide synthase in rats. FASEB J 2003; 17: 932-4.
144. Costa EJ, Shida CS, Biaggi MH, Ito AS, Lamy-Freund MT. How melatonin interacts with lipid bilayers: a study by fluorescence and ESR spectroscopies. FEBS Lett 1997; 416: 103-6.
145. Korkmaz A, Reiter RJ. Epigenetic regulation: a new research area for melatonin? J Pineal Res 2008; 44: 41-4.
146. Benítez-King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res 2006; 40: 1-9.
147. Prieto-Gómez B, Velázquez-Paniagua M, Olivos-Cisneros L, et al. Melatonin attenuates the decrement of dendritic protein MAP-2 immuno-staining in the hippocampal CA1 and CA3 fields of the aging male rat. Neurosci Lett 2008; 448: 56-61.
148. Jarzynkaa MJ, Passeya DK, Johnsona DA, et al. Microtubules Modulate Melatonin receptors involved in phaseshifting circadian activity rhythms: in vitro and in vivo evidence. J Pineal Res 2009; 46: 161-71.
149. Benítez-King G, Ortíz-López L, Jiménez-Rubio G, Ramírez-Rodríguez G. Haloperidol causes cytoskeletal collapse in N1E-115 cells through tau hyperphosphorylation induced by oxidative stress: Implications for neurodevelopment. Eur J Pharmacol 2010; 644: 24-31.
150. Ramirez-Rodriguez G, Ortíz-López L, Domínguez-Alonso A, Benítez-King GA, Kempermann G. Chronic treatment with melatonin stimulates dendrite maturation and complexity in adult hippocampal neurogenesis of mice. J Pineal Res 2011; 50: 29-37.
151. Jiménez-Rubio G, Ortíz-López L, Benítez-King G. Melatonin modulates cytoskeletal organization in the rat brain hippocampus. Neurosci Lett 2012; 511: 47-51.
152. Tardito D, Molteni R, Popoli M, Racagni G. Synergistic mechanisms involved in the antidepressant effects of agomelatine. Eur Neuropsychopharmacol 2012; 22: S482-6.
153. Mishima K, Okawa M, Hishikawa Y, et al. Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psychiatr Scand 1994; 89:1-7.
154. Jiang HK, Wang JY. Diurnal melatonin and cortisol secretion profiles in medicated schizophrenic patients. J Formos Med Assoc 1998; 97: 830-7.
155. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer’s disease. J Pineal Res 2005; 38: 145-54.
156. Cardinali DP, Brusco LI, Liberczuk C, Furio AM. The use of melatonin in Alzheimer’s disease. Neuro Endocrinol Lett 2002; 23: 20-3.
157. Asayama K, Yamadera H, Ito T, et al. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and noncognitive functions in Alzheimer type dementia. J Nippon Med Sch 2003; 70: 334-41.
158. Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001; 58: 1049-52.
159. Jacob S, Poeggeler B, Weishaupt JH, et al. Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients. J Pineal Res 2002; 33: 186-7.
160. Weishaupt JH, Bartels C, Pölking E, et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006; 41: 313-23.
161. Chahbouni M, Escames G, Venegas D, et al. Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. J Pineal Res 2010; 48: 282-9.
162. Tapias V, Cannon JR, Greenamyre JT. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. J Neurosci Res 2010; 88: 420-7.
163. Hamdi A. Melatonin administration increases the affinity of D2 dopamine receptors in the rat striatum. Life Sci 1998; 63: 2115-20.
164. Venero JL, Absi el-H, Cano J, Machado A. Melatonin induces tyrosine hydroxylase mRNA expression in the ventral mesencephalon but not in the hypothalamus. J Pineal Res 2002; 32: 6-14.
165. Alexiuk NA, Vriend J. Melatonin: effects on dopaminergic and serotonergic neurons of the caudate nucleus of the striatum of male Syrian hamsters. J Neural Transm 2007; 114: 549-54.
166. Lin CH, Huang JY, Ching CH, Chuang JI. Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats. J Pineal Res 2008; 44: 205-13.
167. Dardiotis E, Panayiotou E, Feldman ML, et al. Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration. Neurosci Lett 2013; 548: 170-5.
168. Girish KS, Paul M, Thushara RM, et al. Melatonin elevates apoptosis in human platelets via ROS mediated mitochondrial damage. Biochem Biophys Res Commun 2013; 438: 198-204.
169. Krokosz A, Grebowski J, Szweda-Lewandowska Z, Rodacka A, Puchala M. Can melatonin delay oxidative damage of human erythrocytes during prolonged incubation? Adv Med Sci 2013; 58: 134-42.
170. Voordouw BC, Euser R, Verdonk RE, et al. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab 1992; 74: 108-17.
171. Calabresi PA. Diagnosis and management of multiple sclerosis. Am Fam Physician 2004; 70: 1935-44.
172. Lassmann H, Brück W, Lucchinetti C. The immunopathology of multiple sclerosis. An overview. Brain Pathol 2007; 17: 210-8.
173. Hauser SL, Goodwin DS. Multiple sclerosis and other demyelinating diseases. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Eds. Harrison’s principles of internal medicine 17th ed. ; New York: McGraw-Hill Medical; 2008; pp. 2611-21.
174. Cree BAC. Multiple sclerosis. In: Brust JCM, ed. Current diagnosis and treatment in neurology; New York: Lange Medical Books/McGraw-Hill Medical; 2007.
175. Morandi B, Bramanti P, Bonaccorsi I, et al. Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol Res 2008; 57: 1-5.
176. Spiro DB. Early onset multiple sclerosis: a review for nurse practioners. J Pediatr Health Care 2012; 26: 399-408.
177. Goldenberg M. Multiple sclerosis review. P&T 2012; 37: 175-84.
178. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8: 647-56.
179. Sandyk R. The pineal gland and the clinical course of multiple sclerosis. Int J Neurosci 1992; 62: 65-74.
180. Sandyk R, Awerbuch GI. The pineal gland in multiple sclerosis. Int J Neurosci 1991; 61: 61-7.
181. Sandyk R, Awerbuch GI. Nocturnal plasma melatonin and alphamelanocyte stimulating hormone levels during exacerbation of multiple sclerosis. Int J Neurosci 1992; 67: 173-86.
182. Sandyk R, Awerbuch GI. Relationship of nocturnal melatonin levels to duration and course of multiple sclerosis. Int J Neurosci 1994; 75: 229-37.
183. Persinger MA. A potential multiple resonance mechanism by which weak magnetic fields affect molecules and medical problems: the example of melatonin and experimental “multiple sclerosis”. Med Hypotheses 2006; 66: 811-5.
184. Kotini A, Anninos P, Tamiolakis D. MEG mapping in multiple sclerosis patients. Eura Medicophys 2007; 43: 345-8.
185. Sandyk R, Awerbuch GI. Nocturnal melatonin secretion in suicidal patients with multiple sclerosis. Int J Neurosci 1993; 71: 173-82.
186. Sandyk R, Awerbuch GI. Multiple sclerosis: the role of the pineal gland in its timing of onset and risk of psychiatric illness. Int J Neurosci 1993; 72: 95-106.
187. Sandyk R, Awerbuch GI. Pineal calcification and its relationship to the fatigue of multiple sclerosis. Int J Neurosci 1994; 74: 95-103.
188. Akpinar Z, Tokgöz S, Gökbel H, et al. The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis. Psychiatry Res 2008; 2: 253-7.
189. Sandyk R. Diurnal variations in vision and relations to circadian melatonin secretion in multiple sclerosis. Int J Neurosci 1995; 83: 1-6.
190. Natarajan R, Einarsdottir E, Riutta A, et al. Melatonin pathway genes are associated with progressive subtypes and disability status in multiple sclerosis among finnish patients. J Neuroimmunol 2012; 250: 106-10.
191. Sandyk R. Multiple sclerosis: the role of puberty and the pineal gland in its pathogenesis. Int J Neurosci 1993; 68: 209-25.
192. Sandyk R, Awerbuch GI. Multiple sclerosis: relationship between seasonal variations of relapse and age of onset. Int J Neurosci 1993; 71: 147-57.
193. Hutter CD, Laing P. Multiple sclerosis: sunlight, diet, immunology and aetiology. Med Hypotheses 1996; 46: 67-74.
194. Constantinescu CS, Hilliard B, Ventura E, Rostami A. Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. Pathobiology 1997; 65: 190-4.
195. Hansson I, Holmdahl R, Mattsson R. Constant darkness enhances autoimmunity to collagen-induced arthritis in DBA/1 mice. J Neuroimmunol 1990; 27: 79-84.
196. Hansson I, Holmdahl R, Mattsson R. The pineal hormone melatonin exaggerates development of collagen-induced arthritis in mice. J Neuroimmunol 1992; 39: 23-30.
197. Del Gobbo V, Libri V, Villani N, Calio R, Nistico G. Pinealectomy inhibits interleukin-2 production and natural killer activity in mice. Int J Immunopharm 1989; 11: 567-73.
198. Pioli C, Caroleo MO, Nistico G, Doria G. Melatonin increases antigen presentation and amplifies specific and nonspecific signals for T-cell proliferation. Int J Immunopharm 1993; 15: 463-8.
199. Constantinescu CS. Melanin, Melatonin, Melanocyte-Stimulating Hormone, and the Susceptibility to Autoimmune Demyelination: A Rationale for Light Therapy in Multiple Sclerosis. Med Hypotheses 1995; 45: 455-8.
200. Rostami A, Ciric B. Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J Neurol Sci 2013; 333(1-2): 76-87.
201. Maestroni GJM, Conti A, Pierpaoli W. Role of the pineal gland in immunity. I. Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J Neuroimmunol 1986; 13: 19-30.
202. Gong X, Xie Z, Zuo H. A new track for understanding the pathogenesis of multiple sclerosis: from the perspective of early developmental deficit caused by the potential 5-HT deficiency in individuals in high-latitude areas. Med Hypotheses 2008; 71: 580-3.
203. Kang JC, Ahn M, Kim YS, et al. Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. J Vetreter Sci 2001; 2: 85-9.
204. Dringen R. Oxidative and antioxidative potential of brain microglial cells. Antioxid Redox Signal 2005; 7: 1223-33.
205. Witherick J, Wilkins A, Scolding N, Kemp K. Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Autoimmune Dis 2010; 2011: 164608.
206. Van Horssen J, Witte ME, Schreibelt G, de Vries HE. Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta 2011; 1812: 141-50.
207. Bowie A, O’Neill LA. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 2000; 59: 13-23.
208. Tasset I, Agüera E, Gascón F, et al. Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis. Rev Neurol 2012; 54: 449-52.
209. Tasset I, Agüera E, Sánchez-López F, et al. Peripheral oxidative stress in relapsing-remitting multiple sclerosis. Clin Biochem 2012; 45: 440-4.
210. Bahamonde C, Conde C, Agüera E, et al. Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: Relationship to oxidative stress. Eur J Pharmacol 2014; 730: 26-30.
211. Anderson G, Rodríguez M. Multiple sclerosis, seizures, and antiepileptics: role of IL-18: IDO, and melatonin. Eur J Neurol 2011; 18: 680-5.
212. Spokoini R, Kfir-Erenfeld S, Yefenof E, Sionov RV. Glycogen Synthase Kinase-3 plays a central role in mediating glucocorticoidinduced apoptosis. Mol Endocrinol 2010; 24: 1136-50.
213. Miller E, Mrowicka M, Malinowska K, Kedziora J, Majsterek I. The effects of whole-body cryotherapy and melatonin supplementation on total antioxidative status and some antioxidative enzymes in multiple sclerosis patients. Pol Merkur Lekarski 2011; 31: 150-3.
214. Mrowicka M, Garncarek P, Miller E, et al. Effect of melatonin on activity of superoxide dismutase (CuZn-SOD) in erythrocytes of patients during short-and long-term hypokinesis. Wiad Lek 2010; 63: 3-9.
215. Miller E, Walczak A, Majsterek I, Kedziora J. Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course. J Neuroimmunol 2013; 257: 97-101.
216. Melamuh L, Golan D, Luboshitzky R, Lavi I, Miller A. Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J Neurol Sci 2012; 314: 37-40.
217. Gusella JF, Wexler NS, Conneally MP, et al. A polymorphic DNA marker linked to Huntington’disease. Nature 1983; 306: 234-8.
218. Heiser V, Scherzinger E, Boeddrich A, et al. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington’s disease therapy. Proc Natl Acad Sci USA 2000; 97: 6739-44.
219. Goodman AOG, Rogers L, Pilsworth S, et al. Asymptomatic sleep abnormalities are a common early feature in patients with Huntington’s disease. Curr Neurol Neurosci Rep 2011; 11: 211-7.
220. Gutekunst CA, Li SH, Yi H, et al. Nuclear and neurophil aggregates in Huntington’s disease: relationship to neuropathology. J Neurosci 1999; 19: 2522-34.
221. Micale V, Mazzola C, Drago F. Endocannabinoids and neurodegenerative diseases. Pharmacol Res 2007; 56: 382-92.
222. Zuccato C, Liber D, Ramos C, et al. Progressive loss of BDNF in a mouse model of Huntington’s disease and rescue by BDNF delivery. Pharmacol Res 2005; 52: 133-9.
223. Goffredo D, Rigamonti D, Zuccato C, et al. Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington’s Disease. Pharmacol Res 2005; 52: 140-50.
224. Yang SH, Chan AWS. Transgenic Animal Models of Huntington’s Disease. Curr Top Behav Neurosci 2011; 7: 61-85.
225. Ramaswamy S, McBride JL, Kordower JH. Animal Models of Huntington’s Disease. ILAR J 2007; 48: 356-73.
226. Túnez I, Santamaría A. Model of huntington’s disease induced with 3-nitropropionic acid (review). Rev Neurol 2009; 48: 430-4.
227. Túnez I, Tasset I, La Cruz VP, Santamaría A. 3-nitropropionic acid as a tool to study the mechanisms involved in huntington’s disease: past, present and future. Molecules 2010; 15: 878-916.
228. Tasset I, Pérez-De La Cruz V, Elinos-Calderón D, et al. Proctective effect of tert-butylhidroquinone on the quinolinic-acid-induced toxicity in rat striatal slices: Role of the Nrf2-antioxidant response element pathway. NeuroSignals 2010; 18: 24-31.
229. Aziz NA, Pijil H, Frölich M, et al. Delayed onset of the diurnal melatonin rise in patients with Huntington’s disease. J Neurol 2009; 256: 1961-5.
230. Taylor N, Bramble D. Sleep disturbance and Huntington’s disease. Br J Psychiatry 1997; 171: 393.
231. Arnulf I, Nielsen J, Lohmann E, et al. Rapid eye movement sleep disturbances in Huntington disease. Arch Neurol 2008; 65: 482-8.
232. Videnovic A, Leurgans S, Fan W, Jaglin J, Shannon KM. Daytime somnolence and nocturnal sleep disturbances in Huntington disease. Parkinsonism Relat Disord 2009; 15: 471-4.
233. Alders J, Smits M, Kremer B, Naarding P. The role of melatonin in sleep disturbances in end-stage Huntington’s disease. J Neuropsychiatry Clin Neurosci 2009; 21: 226-7.
234. Cuesta M, Aungier J, Morton AJ. Behavioral therapy reverses circadian deficits in a transgenic mouse model of Huntington’s disease. Neurobiol Dis 2014; 63: 85-91.
235. Das A, Wallace IVG, Reiter RJ, et al. Overexpression of melatonin membrane receptors increases calcium-binding proteins and protects VSC4.1 motoneurons from glutamate toxicity through multiple mechanism. J Pineal Res 2013; 54: 58-68.
236. Van Wamelen DJ, Aziz NZ, Anink JJ, et al. Suprachiasmatic nucleus neuropeptide expression in patients with Huntington’s disease. Sleep 2013; 36: 117-25.
237. Mu S, Ouyang L, Liu B, et al. Protective effect of melatonin on 3-NP induce striatal interneuron injury in rats. Neurochem Int 2011; 59: 224-34.
238. Tasset I, Sánchez-López F, Agüera E, et al. NGF and nitrosative stress in patients with Huntington’s disease. J Neurol Sci 2012; 315: 133-6.
239. Tasset I, Agüera E, Olmo-Camacho R, et al. Melatonin improves 3-nitropropionic acid induced behavioral and neurotrophic factors levels. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1944-9.
240. Tasset I, Sánchez F, Túnez I. The molecular bases of Huntington’s disease. The role played +by oxidative stress. Rev Neurol 2009; 49: 424-9.
241. Túnez I, Montilla P, Muñoz MC, Feijóo M, Salcedo M. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington’s disease. J Pineal Res 2004; 37: 252-6.
242. Antunes E, Ricardo C, Folharini C, Wayne C. Correlations between behavioural and oxidative parameters in a rat quinolinic acid model of Huntington’s disease: protective effect of melatonin. Eur J Pharmacol 2013; 701: 65-72.
243. Behan WMH, McDonald M, Darlington LG, Stone TW. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol 1999; 128; 1754-60.
244. Rodríguez-Martínez E, Camacho A, Maldonado PD, et al. Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum. Brain Res 2000; 858: 436-9.
245. Maharaj DS, Maharaj H, Antunes EM, et al. 6-hydroxymelatonin protects against quinolinic-acid-induced oxidative neurotoxicity in the rat hippocampus. J Pharm Pharmacol 2005; 57: 877-81.
246. Reiter RJ, Cabrera J, Sainz RM, et al. Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington’s disease, Alzheimer’s disease and Parkinsonism. Ann NY Acad Sci 1999; 890: 471-85.
247. Tasset I, Pérez-Herrera A, Medina FJ, et al. Extremely lowfrequency electromagnetic fields activate the antioxidant pathway Nrf2 in a Huntington's disease-like rat model. Brain Stimul 2013; 6: 84-6.
248. Túnez I, Sánchez-López F, Agüera E, et al. Important role of oxidative stress biomarkers in Huntington's disease. J Med Chem 2011; 54: 5602-6.
249. Sánchez-López F, Tasset I, Agüera E, et al. Oxidative stress and inflammation biomarkers in the blood of patients with Huntington's disease. Neurol Res 2012; 34: 721-4.
250. Browne SE, Bowling AC, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol 1997; 41: 646-53.
251. Reiter RJ, Tan DX, Qi W, et al. Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol Signals Recept 2000; 9: 161-71.
252. Tan DX, Manchester LD, Sainz RM, et al. Antioxidant strategies in protection against neurodegenerative disorders. Exp Opin Ther Patents 2003; 13: 593-604.
253. Kaur C, Ling EA. Antioxidants and neuroprotection in the adult and developing central nervous system. Curr Med Chem 2008; 15: 3068-80.
254. Leon J, Acuña-Castroviejo D, Sainz RM, et al. Melatonin and mitocondrial function. Life Sci 2004; 75: 765-90.
255. Carpentieri A, Díaz de Barboza G, Areco M, Peralta-López M, Tolosa de Talamoni N. New perspectives in melatonin uses. Pharmacol Res 2012; 65: 437-44.
256. Pandi-Perumal SR, Bahamman AS, Brown GM, et al. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Phys Chem B 2012; 116: 7291-5.
257. Petrosillo G, Moro N, Ruggiero FM, Paradies G. Melatonin inhibits cardiolipin peroxidation in mitochondria and prevents the mitochondrial permeability transition and cytochrome c release. Free Radic Biol Med 2009; 47: 9674-89.
258. Tasset I, Esponola C, Medina FJ, et al. Neuroprotective efectt of carvedilol and melatonin on 3-nitropropionic acid-induced neurotoxicity in neuroblastoma. J Physiol Biochem 2009; 65: 291-6.
259. Montilla P, Feijóo M, Muñoz MC, et al. Effect of melatonin on the oxidative stress in N1E-115 cells is not mediated by mt1 receptors. J Physiol Biochem 2003; 59: 263-8.
260. Peyser CE, Folstein M, Chase GA, et al. Trial of D-alphatocopherol in Huntington’s disease. Am J Psychiatry 1995; 152: 1771-5.
261. Ranen NG, Peyser CE, Coyle JT, et al. A controlled trial of idebenone in Huntington’s disease. Mov Disord 1996; 11: 549-54.
262. Herch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2’dG. Neurology 2006; 66: 250-2.
263. Hyson HC, Kieburtz K, Shoulson I, et al. Safety and tolerability of high-dosage coenzyme Q10 in Huntintgton’s disease and healthy subjects. Mov Disord 2010; 25: 1924-8.
264. Beal MF. Neuroprotective effects of creatine. Amino Acids 2011; 40: 1305-13.
265. Tasset I, Pontes AJ, Hinojosa AJ, de la Torre R, Túnez I. Olive oil reduces oxidative damage in a 3-nitropropionic acid-induced Huntington's disease-like rat model. Nutr Neurosci 2011; 14: 106-11.
266. Túnez I, Montilla P, Muñoz MDC, Medina FJ, Drucker-Colin R. Effect of transcranial magnetic stimulation on oxidative stress induced by 3-nitropropionic acid in cortical synaptosomes. Neurosci Res 2006; 56: 91-5.
267. Túnez I, Drucker-Colin R, Jimena I, et al. Transcranial magnetic stimulation attenuates cell loss and oxidative damage in the striatum induced in the 3-nitropropionic model of Huntington’s disease. J Neurochem 2006; 97: 619-30.
268. Medina FJ, Túnez I. Huntington’s disease: The value of transcranial meganetic stimulation. Curr Med Chem 2010; 17: 2482-91.
269. Tasset I, Medina FJ, Jimena I, et al. Neuroprotective effects of extremely low-frequency electromagnetic fields on a Huntington’s disease rat model: Effects on neurotrophic factors and neuronal density. Neuroscience 2012; 209: 54-63.
270. Nam E, Seung ML, Seong EK, et al. Melatonin protects against neuronal damage induce by 3-nitropropionic acid in rat striatum. Brain Res 2005; 1046; 90-6.
271. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci 1999; 22: 391-7.
272. McIntosh TK, Saatman KE, Raghupathi R. Calcium and the pathogenesis of traumatic CNS injury: Cellular and molecular mechanisms. Neuroscientist 1997; 3: 169-75.
273. Bramlett HM, Dietrich WD. Pathophysiology of cerebral ischemia and brain trauma: Similarities and differences. J Cereb Blood Flow Metab 2004; 24: 133-50.
274. Siesjo BK, Bengtsson F. Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: a unifying hypothesis. J Cereb Blood Flow Metab 1989; 9: 127-40.
275. Back T. Pathophysiology of the ischemic penumbra-revision of a concept. Cell Mol Neurobiol 1998; 18: 621-38.
276. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic/ischemic neuronal death. Ann Rev Neurosci 1990; 13: 171-82.
277. Choi D, Maulucci-Gedde M, Kriegstein AR. Glutamate neurotoxicity in cortical cell culture. J Neurosci 1987; 7: 357-68.
278. Katayama Y, Becker DP, Tamura T, Hovda DA. Massive increases in extracellular potassium and the indiscriminate release of glutamate following concussive brain injury. J Neurosurg 1990; 73: 889-900.
279. Nilsson P, Hillered L, Ponton U. Changes in cortical extracellular levels of energy-related metabolites and amino acids following concussive brain injury in rats. J Cereb Blood Flow Metab 1990; 10: 631-7.
280. Lee SM, Wong MD, Samii A, Hovda DA. Evidence for energy failure following irreversible traumatic brain injury Ann NY Acad Sci 1999; 893: 337-40.
281. Kawamata T, Katayama Y, Hovda DA, Yoshino A, Becker DP. Lactate accumulation following concussive brain injury: the role of ionic fluxes induced by excitatory amino acids. Brain Res 1995; 674: 196-204.
282. Hovda DA, Yoshino A, Kawamata T, Katayama Y, Becker DB. Diffuse prolonged depression of cerebral oxidative metabolism following concussive brain injury n the rat: A cytochrome oxidase histochemistry study. Brain Res 1991; 567: 1-10.
283. Yoshino A, Hovda DA, Kawamata T, Katayama Y, Becker DB. Dynamic changes in local cerebral glucose utilization following cerebral concussion in rats: Evidence of a hyper-and subsequent hypometabolic state. Brain Res 1991; 561: 106-19.
284. Bergsneider M, Hovda DA, Shalmon E, et al. Cerebral hyperglycolysis following severe human traumatic brain injury: a positron emission tomography study. J Neurosurg 1997; 86: 247-51.
285. Passineau MJ, Zhao W, Busto R, et al. Chronic metabolic sequelae of traumatic brain injury: prolonged suppression of somatosensory activation. Am J Physiol Heart Circ Physiol 2000; 279: H924-31.
286. Zhou JN, Liu RY, van Heerikhuize J, Hofman MA, Swaab DF. Alterations in the circadian rhythm of salivary melatonin begin during middle-age. J Pineal Res 2003; 34: 11-6.
287. Mahlberg R, Tilmann A, Salewski L, Kunz D. Normative data on the daily profile of urinary 6-sulfatoxymelatonin in healthy subjects between the ages of 20 and 84. Psychoneuroendocrinology 2006; 31: 634-41.
288. Ritzenthaler T, Nighoghossian N, Berthiller J, et al. Nocturnal urine melatonin and 6-sulphatoxymelatonin excretion at the acute stage of ischaemic stroke. J Pineal Res 2009; 46: 349-352.
289. Zimmerman RA, Bilaniuk LT. Age-related incidence of pineal calcification detected by computed tomography. Radiology 1982; 142: 659-62.
290. Kitkhuandee A, Sawanyawisuth K, Johns NP, Kanpittaya J, Johns J. Pineal Calcification is Associated with Symptomatic Cerebral Infarction. J Stroke Cerebrovasc Dis 2013; S1052-3057: 00015-3.
291. Park OK, Yoo KY, Lee CH, et al. Arylalkylamine Nacetyltransferase (AANAT) is expressed in astrocytes and melatonin treatment maintains AANAT in the gerbil hippocampus induced by transient cerebral ischemia. J Neurol Sci 2010; 294: 7-17.
292. Weil ZM, Karelina K, Su AJ, et al. Time-of-day determines neuronal damage and mortality after cardiac arrest. Neurobiol Dis 2009; 36: 352-60.
293. Chen HY, Hung YC, Chen TY, et al. Melatonin improves presynaptic protein, SNAP-25: expression and dendritic spine density and enhances functional and electrophysiological recovery following transient focal cerebral ischemia in rats. J Pineal Res 2009; 47: 260-70.
294. Alonso-Alconada D, Alvarez A, Lacalle J, Hilario E. Histological study of the protective effect of melatonin on neural cells after neonatal hypoxia-ischemia. Histol Histopathol 2012; 27: 771-83.
295. Balduini W, Carloni S, Perrone S, et al. The use of melatonin in hypoxic-ischemic brain damage: an experimental study. J Matern Fetal Neonatal Med 2012; 25: 119-24.
296. Chern CM, Liao JF, Wang YH, Shen YC. Melatonin ameliorates neural function by promoting endogenous neurogenesis through the MT2 melatonin receptor in ischemic-stroke mice. Free Radic Biol Med 2012; 52: 1634-47.
297. Kilic E, Ozdemir YG, Bolay H, Keleştimur H, Dalkara T. Pinealectomy aggravates and melatonin administration attenuates brain damage in focal ischemia. J Cereb Blood Flow Metab 1999; 19: 511-6.
298. Lin HW, Lee EJ. Effects of melatonin in experimental stroke models in acute, sub-acute, and chronic stages. Neuropsychiatr Dis Treat 2009; 5: 157-62.
299. Lee MY, Kuan YH, Chen HY. et al. Intravenous administration of melatonin reduces the intracerebral cellular inflammatory response following transient focal cerebral ischemia in rats. J Pineal Res 2007; 42: 297-309.
300. Kilic E, Kilic U, Reiter RJ, Bassetti CL, Hermann DM. Tissueplasminogen activator-induced ischemic brain injury is reversed by melatonin: role of iNOS and Akt. J Pineal Res 2005; 39: 151-5.
301. Koh PO. Melatonin attenuates the focal cerebral ischemic injury by inhibiting the dissociation of pBad from 14-3-3. J Pineal Res 2008: 44: 101-6.
302. Lee EJ, Wu TS, Lee MY, et al. Delayed treatment with melatonin enhances electrophysiological recovery following transient focal cerebral ischemia in rats. J Pineal Res 2004; 36: 33-42.
303. Letechipía-Vallejo G, López-Loeza E, Espinoza-González V, et al. Long-term morphological and functional evaluation of the neuroprotective effects of post-ischemic treatment with melatonin in rats. J Pineal Res 2007; 42: 138-46.
304. Ma Y, Feng Q, Ma J, et al. Melatonin ameliorates injury and specific responses of ischemic striatal neurons in rats. J Histochem Cytochem 2013; 61: 591-605.
305. Tai SH, Chen HY, Lee EJ, et al. Melatonin inhibits postischemic matrix metalloproteinase-9 (MMP-9) activation via dual modulation of plasminogen/plasmin system and endogenous MMP inhibitor in mice subjected to transient focal cerebral ischemia. J Pineal Res 2010; 49: 332-41.
306. Jang JW, Lee JK, Lee MC, et al. Melatonin reduced the elevated matrix metalloproteinase-9 level in a rat photothrombotic stroke model. J Neurol Sci 2012; 323: 221-7.
307. Kilic U, Yilmaz B, Ugur M, et al. Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia. J Pineal Res 2012; 52: 228-35
308. Lee CH, Yoo KY, Choi JH, et al. Melatonin's protective action against ischemic neuronal damage is associated with up-regulation of the MT2 melatonin receptor. J Neurosci Res 2010; 88: 2630-40.
309. Nair SM, Rahman RM, Clarkson AN, et al. Melatonin treatment following stroke induction modulates L-arginine metabolism. J Pineal Res 2011; 51: 313-23.
310. Han F, Tao RR, Zhang GS, et al. Melatonin ameliorates ischemiclike injury-evoked nitrosative stress: Involvement of HtrA2/PED pathways in endothelial cells. J Pineal Res 2011; 50: 281-91.
311. Koh PO. Melatonin regulates the calcium-buffering proteins, parvalbumin and hippocalcin, in ischemic brain injury. J Pineal Res 2012; 53: 358-65.
312. Villapol S, Fau S, Renolleau S, et al. Melatonin promotes myelination by decreasing white matter inflammation after neonatal stroke. Pediatr Res 2011; 69: 51-5.
313. Tang Y, Cai B, Yuan F, et al. Melatonin pretreatment improves the survival and function of transplanted mesenchymal stem cells after focal cerebral ischemia. Cell Transplant 2014; Epub ahead of print].
314. Kilic U, Yilmaz B, Reiter RJ, Yüksel A, Kilic E. Effects of memantine and melatonin on signal transduction pathways vascular leakage and brain injury after focal cerebral ischemia in mice. Neuroscience 2013; 237: 268-76.
315. Ozyener F, Çetinkaya M, Alkan T, et al. Neuroprotective effects of melatonin administered alone or in combination with topiramate in neonatal hypoxic-ischemic rat model. Restor Neurol Neurosci 2012; 30: 435-44.
316. Ahmad A, Khan MM, Ishrat T, et al. Synergistic effect of selenium and melatonin on neuroprotection in cerebral ischemia in rats. Biol Trace Elem Res 2011; 139: 81-96.
317. Poluéktov MG, Levin II, Boĭko AN, et al. The results of Russian multicenter open-label observational study of the efficacy and safety of мelaxen (melatonin) for the treatment of disordered sleep in patients with chronic cerebral ischemia. Zh Nevrol Psikhiatr Im S S Korsakova 2012; 112: 26-31.
318. Sunami E, Usuda K, Nishiyama Y, et al. A preliminary study of fluvoxamine maleate on depressive state and serum melatonin levels in patients after cerebral infarction. Intern Med 2012; 51: 1187-93.